INTRODUCTION
The transforming growth factor-A (TGFA) cytokine superfamily comprises TGFAs, activins, nodals, and bone morphogenetic proteins. When bound to their specific receptors, these cytokines induce phosphorylation-mediated activation of intracellular mediators termed Smads. The activated Smads are translocated to the nucleus where they orchestrate the transcription of multiple target genes.
Abnormalities of TGFA activity have been implicated in a diverse spectrum of diseases, including cancer (colonic, gastric, and pancreatic) (1), renal disease (2), cirrhosis, pulmonary fibrosis, cardiomyopathy, and hydrocephalus. Impaired transduction of TGFA signaling has also recently been implicated in Alzheimer disease (AD). TGFA was reported to colocalize with amyloid A plaques (3) and neurofibrillary tangles (NFTs) (4, 5) , and TGFA mRNA levels were 3-fold higher in the frontal cortex of patients with AD than in control subjects (6) . Several groups recently reported aberrant accumulation of phosphorylated Smad 2/3 (pSmad2/3) within the cytoplasm of NFT-containing neurons in AD (7Y9); such neurons were less likely to contain nuclear pSmad2/3 (7), suggesting that NFTs interfere with the nuclear translocation of activated Smads and thereby with TGFA signaling.
Several neurodegenerative diseases other than AD are characterized by the formation of neuronal or glial inclusions composed of either phospho-tau or other proteins such as >-synuclein. Our aim in the present study was to find out whether cytoplasmic accumulation of pSmad2/3 is specific to NFTs in AD or occurs in other neurodegenerative diseases with cytoplasmic inclusions, composed of either phospho-tau or >-synuclein.
MATERIALS AND METHODS

Brain Tissue
Frozen and fixed brain tissue was obtained from cases of dementia with Lewy bodies (DLB) (n = 3), Pick disease (n = 2), progressive supranuclear palsy (PSP) (n = 2), corticobasal degeneration (CBD) (n = 2), multisystem atrophy (MSA) (n = 1), AD (n = 2) and controls (n = 2). Further information relating to these cases is shown in the Table. The study was approved by the Frenchay Research Ethics Committee.
Immunoperoxidase Staining
Paraffin sections 7 Km in thickness were cut from blocks of frontal and temporal lobes, basal ganglia, and midbrain. The sections were labeled as described previously (7) with antibody to pSmad2/3 (1:8000, Santa Cruz sc-11769R, raised against a pSmad3 peptide sequence; Autogen Bioclear, Mile Elm, UK) after citrate buffer (pH 6) microwave pretreatment. Bound antibody was visualized using a Super Sensitive Polymer-HRP detection system (Biogenex, Berkshire, UK) with diaminobenzidine as the chromogen.
Tau inclusions characteristic of Pick disease, PSP, and CBD were identified by immunolabeling sections with antibody to Ser 202 phospho-tau (1:3000, AT8; Innogenetics, Gent, Belgium). In cases of Pick disease and PSP, further sections were labeled with antibody to 3-repeat tau (1:8000, #05-803; Upstate Biotechnology, Chandlers Ford, UK) and 4-repeat tau (1:400, #05-804; Upstate) after pretreatment by microwaving in citrate buffer (pH 6). Sections from DLB and MSA cases were immunolabeled with antibody to >-synuclein (1:800, VP-A106; Vector Laboratories, Peterborough, UK) after pretreatment with formic acid and EDTA (pH 8) to demonstrate the Lewy bodies and neurites and the glial cytoplasmic inclusions. Sections were incubated overnight with primary antibodies at 4-C. Bound antibody was visualized using the Super Sensitive Polymer-HRP detection system.
The specificity of the pSmad2/3 antibody was assessed by preadsorption with the pSmad3 immunizing peptide (sc-11769P) used by Santa Cruz to raise the antibody. The pSmad2/3 antibody (1:8000) was incubated overnight at 4-C with a 20-fold molar excess (666 KM) of the peptide before immunolabeling of sections as above.
Western Blotting
To examine further the specificity of the pSmad2/3 antibody, we performed Western blots on right frontal cortex from 2 cases of Pick disease, 1 case of PSP, 2 cases of DLB, and 2 normal controls. The tissue had been stored at Y80-C before use; 500-mg samples of frontal cortex were homogenized in lysis buffer (0.1 M NaCl, 10 mM Tris (pH 6), 1 KM phenymethylsulfonyl fluoride, 1 Kg/mL aprotinin, and 1% sodium dodecyl sulfate in distilled water) with the aid of an automated homogenizer (Precellys 24; Stretton Scientific, Stretton, UK). The homogenate was centrifuged at 16,000g for 15 minutes at 4-C, and the supernatant was removed and stored at Y80-C until required.
From each homogenate, 15 Kg of total protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 4% to 20% Tris-HCl gels (National Diagnostics (UK) LtdYAGTC Bioproducts, East Riding of Yorkshire, UK). Molecular weight markers (ECL DualVue; GE Healthcare UK Limited, Chalfont St. Giles, Buckinghamshire, UK), were included. The proteins were transferred to nitrocellulose membrane (GE Healthcare UK Limited) overnight at 4-C. The membrane was then blocked in 10% nonfat milk in Tris-buffered saline-Tween (TBS-T) (0.5%) for 1 hour and incubated with antibody to pSmad2/3 (diluted 1:200 in 5% nonfat milk/TBS-T) for 1 hour on a rocking platform. After the membrane was washed in TBS-T, it was incubated with peroxidase-conjugated anti-rabbit IgG (1:5000 in 5% nonfat milk/TBS-T) for 1 hour and immunolabeled bands were visualized using enhanced chemiluminescence (ECL Plus kit; Amersham Biosciences UK, Ltd.).
Double Immunofluorescence
The distribution of pSmad2/3 in relation to Pick bodies and tau-positive inclusions found in PSP and CBD cases was assessed in sections double immunolabeled with antibodies to pSmad2/3 (1:500) and Ser 202 phospho-tau (1:800). For DLB cases, the relationship between pSmad2/3 and >-synuclein was assessed in sections pretreated with formic acid, EDTA (pH 8), and citrate buffer (pH 6) and incubated with antibody to pSmad2/3 (1:500) and >-synuclein (1:200). Bound antibodies were visualized with species-specific fluorochromes, and the sections were counterstained with Hoechst nuclear stain (Fluka 14533; Sigma Aldrich, Poole, UK).
For all of the immunofluorescence studies, monochromatic images were acquired and merged using a Nikon E80i microscope (Nikon, Japan) and iQ software (Andor Technology, Belfast, UK).
RESULTS
Distribution of pSmad2/3 in Pick Disease, PSP, and Corticobasal Degeneration
Ser 202 phospho-tau antibody labeled Pick bodies in the pyramidal cell layer of the hippocampus (Fig. 1A) and in many neurons in the temporal neocortex (Fig. 1C) . The antibody also labeled neocortical astrocytic inclusions (Fig.  1C) . In the same cases, the distribution of pSmad2/3 was strikingly similar to that of phospho-tau, encompassing Pick bodies (Fig. 1B, D ) and glial inclusions (Fig. 1D ), but pSmad2/3 was, in addition, present in most neuronal and many glial nuclei (Fig. 1B, D) . Accumulation of pSmad2/3 was particularly striking in the dentate gyrus, where both Pick bodies and neuronal nuclei were labeled ( Fig. 2A) . The swollen Pick cells in the neocortex showed patchy D) immunolabeling of the CA1 field of the hippocampus and the temporal neocortex. In the CA1 field, Pick bodies are strongly immunopositive for phospho-tau (A) and also for pSmad2/3 (B). Antibody to pSmad2/3 also labels neuronal nuclei (arrowheads). In the neocortex (C), phosphotau is demonstrable in neurons and astrocytes (arrows). Antibody to pSmad2/3 (D) labels the Pick bodies and astrocytic inclusions, as well as some nuclei (see, for example, arrowhead), predominantly neuronal. cytoplasmic pSmad2/3 immunopositivity (Fig. 2B) . Preadsorption with pSmad 3 immunizing peptide completely prevented the immunolabeling of nuclei or cytoplasmic inclusions (Fig. 2C, D) . Antibody specificity was further confirmed by Western blotting, which revealed a dominant band at approximately 50 kDa in Pick disease, PSP, and DLB cases, but only weak labeling of control brain (Fig. 3) . In PSP cases, phospho-tau antibody labeled globose NFTs in the basal ganglia, subthalamus, and midbrain, and scattered astrocytic and oligodendroglial inclusions, both coiled bodies and interfascicular threads. The oligodendroglial inclusions were particularly prominent within the subcortical white matter, internal capsule (Fig. 4A) and basal ganglia. The distribution of pSmad2/3 was virtually identical to that of phospho-tau and included coiled bodies (Fig. 4B) , interfascicular threads, astrocytic inclusions, and globose NFTs (Fig. 4C ) in addition to many neuronal and some astrocytic and oligodendroglial nuclei.
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Labeling of sections from the Pick disease and PSP cases with antibodies specific for 3-repeat (3R) or 4-repeat (4R) tau showed the inclusions in Pick disease to be immunopositive for 3R but not 4R tau (Fig. 5A, B) . Conversely, in PSP, the inclusions were immunopositive for 4R tau, and although the 3R tau antibody did produce some weak nonspecific labeling of Nissl substance in PSP, the glial inclusions and NFTs were not labeled with this antibody. In the CBD cases, phospho-tau antibody labeled neuronal inclusions in the substantia nigra and astrocytic inclusions in the cerebral cortex and basal ganglia, including the characteristic astrocytic plaques (Fig. 6A) . Antibody to pSmad2/3 labeled the neuronal inclusions but not the full extent of the astrocytic plaques, only scattered thread-like processes in the same regions of cortex within which astrocytic plaques were demonstrable with antibody to phospho-tau (Fig. 6B) . Ballooned neurons in the neocortex were only weakly immunopositive for pSmad2/3 (Fig. 6C) .
Distribution of pSmad 2/3 in DLBs and MSA
In the DLB cases, the antibody to >-synuclein labeled Lewy bodies and neurites in the substantia nigra and cerebral cortex (Fig. 7A) . In the same cases, pSmad2/3 was readily demonstrable in neuronal nuclei and in plaque-associated dystrophic neurites but not in cortical Lewy bodies (Fig.  7B) . Similarly, pSmad2/3 was present in neuronal nuclei and some glial nuclei in the substantia nigra but not Lewy bodies or pale bodies (Fig. 7C) .
In the MSA case there were numerous >-synuclein-positive glial cytoplasmic inclusions, including the basal ganglia (Fig. 8A) , internal capsule, and midbrain. The putamen also included >-synuclein-positive neuronal cytoplasmic inclusions. Neither the glial nor the neuronal inclusions were immunopositive for pSmad2/3 (Fig. 8B) .
Colocalization of pSmad2/3 With Inclusion Bodies
To assess the extent of colocalization of pSmad2/3 with the various types of cytoplasmic inclusions we used double immunofluorescence for pSmad2/3 and for either Ser 202 phospho-tau or >-synuclein. In Pick disease, pSmad2/ 3 colocalized with phospho-tau in Pick bodies in the dentate gyrus (Fig. 9AYC ) and CA1 region of the hippocampus (Fig.  9DYF) , where pSmad2/3-positive, phospho-tau-negative granulovacuolar inclusions were also evident (Fig. 9F,  arrowhead) . In DLB, pSmad2/3 was seen within many neuronal nuclei, including those of Lewy body-containing neurons, but it was never observed to colocalize with either Lewy bodies (Fig. 9GYJ) or Lewy neurites (Fig. 9KYN) . In CBD there was some colocalization of pSmad2/3 with astrocytic inclusions, although the extent of pSmad2/3 labeling in this disease was less than that of phospho-tau (Fig. 9OYR) . In PSP, pSmad2/3 showed extensive colocalization with phospho-tau in coiled bodies (Fig. 9SYU ) and globose NFTs (Fig. 9VYX) .
DISCUSSION
We have shown that pSmad2/3 accumulates within phospho-tau-positive inclusions in Pick disease, PSP, and CBD, extending our previous observations on the colocalization of pSmad2/3 with NFTs in AD (7) and indicating that the binding of pSmad2/3 to phospho-tau cytoplasmic inclusions is not disease-specific. The present findings indicate that pSmad2/3 is not, however, associated with >-synuclein cytoplasmic inclusions in DLB or MSA. The binding of pSmad2/3 to inclusions in Pick disease, PSP, and CBD seems not to reduce nuclear pSmad2/3 to the same, obvious extent that it does in AD (7), although the possibility of some reduction in nuclear pSmad2/3 in these other diseases cannot be excluded by the methods used in the present study.
Dong et al (10) reported that Smads 2 and 3 were sequestered by microtubules but released on stimulation of cells with TGFA. The use of nocodazole to disrupt the microtubules resulted in Smad phosphorylation and nuclear translocation even in the absence of TGFA, an effect that was reversed by treatment with the microtubule-stabilizing drug, paclitaxel (Taxol) (10) . Under normal physiological conditions, the integrity of the microtubule assembly is maintained by the binding of tau protein, and the ability of tau to stabilize microtubules is inversely related to its phosphorylation state. When tau becomes hyperphosphorylated it is no longer able to stabilize microtubules.
In diseases such as AD, PSP, CBD, and Pick disease, the hyperphosphorylation of tau and resulting fragmentation of microtubules would be expected to cause the release and activation of Smads 2 and 3. The fate of the activated pSmad2/3 may depend on the integrity and phosphorylation state of other parts of the cytoskeleton. In otherwise normal cells, the activated pSmad2/3 is translocated to the nucleus, as in the study of Dong et al (10) . In neurons and glia that contain hyperphosphorylated tau inclusions some of the pSmad2/3 is retained in the cytoplasm, in association with those inclusions. Whereas inactivated Smads 2 and 3 are sequestered by microtubules, our data suggest that activated pSmad2/3 is sequestered by hyperphosphorylated tau.
In our previous study we reported that in AD, many neurons with cytoplasmic pSmad2/3 had no detectable pSmad2/3 within the nucleus (7), a finding that was also noted by Ueberham et al (9) . In PSP, CBD, and Pick disease this did not seem to be the case. The reason for the difference is not clear. It may simply be that the amount of hyperphosphorylated tau within the cytoplasm is greater in AD than in these other diseases, and hence more pSmad2/3 is sequestered. If less pSmad2/3 is sequestered by Pick bodies, coiled bodies, or astrocytic inclusions than by NFTs, more may be free to enter the nucleus. However, it remains possible that the lack of nuclear pSmad2/3 in many neurons in AD reflects abnormalities other than, or in addition to, the sequestration of pSmad2/3 by NFTs.
Our present findings suggest that the binding of pSmad2/3 to phospho-tau is not dependent on the number of tau microtubule-binding domains. NFTs in AD are composed of 3R and 4R tau in an approximately equal ratio (11), Pick bodies are composed predominantly of 3R tau (12) , and PSP inclusions are composed predominantly of 4R tau (13) , yet pSmad2/3 and phospho-tau were colocalized in all of these diseases. One unexpected finding was the less extensive binding of antipSmad2/3 than anti-phospho-tau to the astrocytic inclusions in CBD; these inclusions, like those in PSP, consist mainly of 4R tau (13) . It is possible that the tau inclusions in astrocytes in CBD undergo an additional post-translational modification that reduces the binding of pSmad2/3. Alternatively, there may be less activation of Smads and therefore less available cytoplasmic pSmad2/3 in astrocytes in this disease.
In conclusion, our findings indicate that hyperphosphorylated tau, but not >-synuclein, binds pSmad2/3 within the cytoplasm of neurons and glial cells in a range of neurodegenerative diseases. This binding has the potential to impede the transduction of TGFA signals. The preservation of neuronal nuclear immunopositivity for pSmad2/3 in Pick disease, PSP, and CBD may mean that the impact on pSmad2/3-mediated signaling is less pronounced in these diseases than in AD. We suggest that further investigations are warranted into the mechanisms of the interactions between tau, Smads, and microtubules and the consequences Labeling of a section from the same area for pSmad2/3 (B) reveals many immunopositive neuronal nuclei and some dystrophic neurites associated with Alzheimer-type plaques. Lewy bodies (arrowhead to one) are difficult to pick out in the section but appear unlabeled. In the substantia nigra (C), there is no detectable pSmad2/3 in either a Lewy body (arrowhead) or a pale body (arrow).
